logo
  

Beazer Homes USA Q3 Loss Widens On Extinguishment Of Debt - Quick Facts

Beazer Homes USA, Inc. (BZH) reported a third-quarter loss from continuing operations of $13.19 million or $0.50 per share, compared to a loss of $5.44 million or $0.22 per share, prior year. The company reported $6.6 million in income from continuing operations, excluding a $19.8 million loss on the extinguishment of debt, related to the refinancing transaction in April.

Operating income increased year-over-year to $15.09 million from $8.47 million.

On average, nine analysts polled by Thomson Reuters expected the company to report profit per share of $0.15 for the quarter. Analysts' estimates typically exclude special items.

Total revenue increased to $354.67 million from $314.44 million, a year ago. Analysts expected revenue of $360.13 million for the quarter.

"For the third quarter, we recorded strong gross margins, higher average sales prices anda sales absorption rate that was among the highest in our peer group. This led to a substantial improvement in Adjusted EBITDA and enabled us to report income from homebuilding operations in our third quarter for the first time in nearly a decade. We believe our improved operational and financial results will allow us to report a full year of profitability for fiscal 2014 and further growth in the years ahead," said Allan Merrill, CEO of Beazer Homes.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
French drug major Sanofi reported Thursday weak profit in its first quarter, despite higher net sales. The company also maintained its fiscal 2024 outlook. Sanofi shares were gaining around 4 percent in Paris trading as well as in pre-market activity on the Nasdaq. While reporting financial results for the first quarter on Wednesday, medical devices company Boston Scientific Corp. (BSX) raised its adjusted earnings and net sales growth guidance for the full-year 2024. For fiscal 2024, the company now projects earnings in a range of $1.43 to $1.48 per share and... Shares of Roche Holding AG were losing around 3 percent in Switzerland after the drug major reported weak sales in its first quarter and confirmed fiscal 2024 outlook. Excluding COVID-19-related products, quarterly sales increasedy 7 percent. For fiscal 2024, Roche continues to expect an increase in group sales in the mid single digit range at constant exchange rates.

This week, we feature Nigeria’s combat with meningitis, Hostile takeover bid for Vanda Pharma, US opioid crisis, Sammy’s Milk’s safety concerns, and X4’s Mavorixafor’s fast-track status.

View More Videos
RELATED NEWS
Follow RTT